-

ATUM Awarded EcoVadis Silver Medal Rating for its Sustainability Performance

Gold-standard industry rating further validates ATUM’s commitment to business sustainability and places the company among the top performers globally

NEWARK, Calif.--(BUSINESS WIRE)--ATUM, a global specialist and industry leader in bioengineering solutions, today announced that it has been awarded the prestigious Silver Medal rating from EcoVadis, the world’s most trusted provider of business sustainability ratings. This milestone is the first year ATUM has been recognized by EcoVadis and places the company in the top 15% (85th percentile) of companies rated by EcoVadis in the Scientific Research and Development industry. Among all companies rated by EcoVadis, ATUM ranks at the 74th percentile globally.

“At ATUM, we are immensely proud to be recognized with the EcoVadis Silver Medal rating, which underscores our unwavering dedication to sustainability, diversity, equity, and business ethics,” said Jeremy Minshull, Ph.D., Chief Executive Officer of ATUM. “This achievement is a testament to our exceptional team's relentless pursuit of excellence and innovation in the biotechnology industry, all while upholding the highest standards of social and environmental responsibility. We believe that true progress is defined not only by scientific advancements but also by the positive impact we can make on our planet and for the people who inhabit it.”

Each year, EcoVadis evaluates 21 separate sustainability criteria across four core themes: Environment, Labor & Health Rights, Ethics, and Sustainable Procurement. EcoVadis’ business sustainability ratings are based on international standards such as the Ten Principles of the UN Global Compact, the International Labour Organization (ILO) conventions, the Global Reporting Initiative (GRI) standards, and the ISO 26000 standard. The ratings provide an evidence-based analysis on performance and an actional roadmap for continuous improvement. More than 85,000 companies globally have been rated by EcoVadis.

“It is my mission to promote and expand the Environmental, Social and Governance (ESG) initiatives at ATUM, reinforcing our dedication to corporate social responsibility. We are developing a roadmap, aligned with the Science-Based Targets initiative, which will guide our commitment to significantly reduce our carbon footprint and ultimately achieve net-zero emissions,” said Joseph Higdon, Director of Facilities and Sustainability at ATUM. “Through the EcoVadis assessment, our ESG committee is proud to showcase ATUM’s deep commitment to our employees, customers, and the global community.”

To learn more about the EcoVadis ratings, please visit: www.EcoVadis.com/suppliers.

About ATUM

ATUM is a fully integrated Californian based CRDO (Contract Research & Development Organization) biotechnology industry leader. ATUM, over the last two decades, has served life science researchers by delivering the highest quality services including but not limited to Gene Design and Gene Synthesis, Protein Engineering, Protein Production, Leap-In Transposase®, Cell Line Development, and Master Cell Banking (MCB). With a state-of-the-art machine learning platform, proprietary algorithms and thanks to its fully integrated Laboratory Information Management System (LIMS), ATUM takes you from virtual sequence to MCB with a click of a button. ATUM provides a continual commitment to innovation where services are built on bioengineered solutions to bring speed to market, supporting you from pre-clinical research through IND and beyond. Contact us today for more information at www.atum.bio.

Contacts

Cheryl Sturgis
Head of Marketing
csturgis@atum.bio

ATUM


Release Summary
Gold-standard industry rating further validates ATUM’s commitment to business sustainability.
Release Versions

Contacts

Cheryl Sturgis
Head of Marketing
csturgis@atum.bio

Social Media Profiles
More News From ATUM

ATUM Launches the discoCHO™ Discovery Cell Line for Rapid and Robust Transient Production of Biologics with Manufacturing in Mind

NEWARK, Calif.--(BUSINESS WIRE)--ATUM, a leading US-based provider of integrated biologics solutions, proudly announces the launch of the CHO-K1-derived discoCHO™ cell line for transient protein production. ATUM’s discoCHO enables robust transient therapeutic protein expression displaying critical quality attributes similar to those of the stable CHO-K1 manufacturing cell line miCHO-GS. CHO-K1 cells are the dominant cell line used in manufacturing protein-based biologics. However, CHO-K1-derive...

ATUM Partners with Anagram Therapeutics to Extend Collaboration to Develop Orally Delivered Enzyme Therapies for Malabsorption and Nutrient Metabolism Disorders

NEWARK, Calif.--(BUSINESS WIRE)--ATUM, a global specialist and industry leader in bioengineering solutions, today announced an expanded partnership with Anagram Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to improving the lives of people with cystic fibrosis (CF) and other rare diseases. The expanded relationship follows a successful partnership that accelerated delivery of ANG003 into a clinical study recently initiated in people with cystic fibrosis. Together, the...

ATUM Announces Leap-In Transposase® Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics

NEWARK, Calif.--(BUSINESS WIRE)--ATUM, a global specialist and industry leader in bioengineering solutions, today announced the signing of a full licensing agreement for the Leap-In Transposase® technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines. Under the terms of the agreement, ATUM will provide Codiak access to its Leap-In Transposase® technology to generate mammalian cells expressi...
Back to Newsroom